Alnylam Pharmaceuticals (ALNY) shares ended the last trading session 5.3% higher at $165.70. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 5.4% gain over the past four weeks. The sudden rise in the stock price has likely been driven by the growing optimism of investors regarding Amvuttra’s (vutrisiran) potential to earn increasing revenues for the company. The drug, approved for treating adult patients with polyn ...